Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/10/2026

1. COO
2. CHWY
3. AVAV
4. SPY
5. ASO
6. AAPL
7. PLTR
8. NAVN
9. ORCL
10. USO

Go back to Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3
(NASDAQ: ALMS) Delayed: 9.85 +0.05 (0.51%)
Previous Close $9.80    52 Week High $ 
Open $10.55    52 Week Low $ 
Day High $10.55    P/E N/A 
Day Low $9.65    EPS $ 
Volume 2,730,020